targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000043591 | EFO_0003144 | NCT00953303 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 335,007,450,137 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00953303 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 335,007,450,137 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03026088 | Terminated | 4 | 2017-03-21 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,533,873 | Limited beta-blocker naive participants among newly diagnosed heart failure participants, which led barrier to the recruitments. | Phase 4 | 21/03/2017 | Terminated | 29/01/2020 | 26/12/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03026088 | Terminated | 4 | 2017-03-21 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,533,873 | Limited beta-blocker naive participants among newly diagnosed heart failure participants, which led barrier to the recruitments. | Phase 4 | 21/03/2017 | Terminated | 29/01/2020 | 26/12/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03026088 | Terminated | 4 | 2017-03-21 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,533,873 | Limited beta-blocker naive participants among newly diagnosed heart failure participants, which led barrier to the recruitments. | Phase 4 | 21/03/2017 | Terminated | 29/01/2020 | 26/12/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03026088 | Terminated | 4 | 2017-03-21 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,533,873 | Limited beta-blocker naive participants among newly diagnosed heart failure participants, which led barrier to the recruitments. | Phase 4 | 21/03/2017 | Terminated | 29/01/2020 | 26/12/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03026088 | Terminated | 4 | 2017-03-21 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,533,873 | Limited beta-blocker naive participants among newly diagnosed heart failure participants, which led barrier to the recruitments. | Phase 4 | 21/03/2017 | Terminated | 29/01/2020 | 26/12/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03026088 | Terminated | 4 | 2017-03-21 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,533,873 | Limited beta-blocker naive participants among newly diagnosed heart failure participants, which led barrier to the recruitments. | Phase 4 | 21/03/2017 | Terminated | 29/01/2020 | 26/12/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01375335 | Suspended | 4 | 2011-06-01 | Suspended | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,534,271 | Insufficient patient eligible for recruitment | Phase 4 | 30/06/2011 | Suspended | 07/08/2013 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01375335 | Suspended | 4 | 2011-06-01 | Suspended | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,534,271 | Insufficient patient eligible for recruitment | Phase 4 | 30/06/2011 | Suspended | 07/08/2013 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01375335 | Suspended | 4 | 2011-06-01 | Suspended | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,534,271 | Insufficient patient eligible for recruitment | Phase 4 | 30/06/2011 | Suspended | 07/08/2013 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01375335 | Suspended | 4 | 2011-06-01 | Suspended | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,534,271 | Insufficient patient eligible for recruitment | Phase 4 | 30/06/2011 | Suspended | 07/08/2013 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01375335 | Suspended | 4 | 2011-06-01 | Suspended | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,534,271 | Insufficient patient eligible for recruitment | Phase 4 | 30/06/2011 | Suspended | 07/08/2013 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01375335 | Suspended | 4 | 2011-06-01 | Suspended | stopped | Phase IV | Phase III+ | Phase II+ | 455,266,534,271 | Insufficient patient eligible for recruitment | Phase 4 | 30/06/2011 | Suspended | 07/08/2013 | null | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03209180 | Unknown status | 4 | 2016-10-27 | null | null | Phase IV | Phase III+ | Phase II+ | 472,446,403,886 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03209180 | Unknown status | 4 | 2016-10-27 | null | null | Phase IV | Phase III+ | Phase II+ | 472,446,403,886 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03209180 | Unknown status | 4 | 2016-10-27 | null | null | Phase IV | Phase III+ | Phase II+ | 472,446,403,886 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03209180 | Unknown status | 4 | 2016-10-27 | null | null | Phase IV | Phase III+ | Phase II+ | 472,446,403,886 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03209180 | Unknown status | 4 | 2016-10-27 | null | null | Phase IV | Phase III+ | Phase II+ | 472,446,403,886 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT03209180 | Unknown status | 4 | 2016-10-27 | null | null | Phase IV | Phase III+ | Phase II+ | 472,446,403,886 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00446017 | Completed | 3 | 2003-06-01 | null | null | null | Phase III+ | Phase II+ | 618,475,291,838 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00446017 | Completed | 3 | 2003-06-01 | null | null | null | Phase III+ | Phase II+ | 618,475,291,838 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00446017 | Completed | 3 | 2003-06-01 | null | null | null | Phase III+ | Phase II+ | 618,475,291,838 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00446017 | Completed | 3 | 2003-06-01 | null | null | null | Phase III+ | Phase II+ | 618,475,291,838 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00446017 | Completed | 3 | 2003-06-01 | null | null | null | Phase III+ | Phase II+ | 618,475,291,838 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00446017 | Completed | 3 | 2003-06-01 | null | null | null | Phase III+ | Phase II+ | 618,475,291,838 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00885651 | Unknown status | 4 | 2008-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 704,374,637,739 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00885651 | Unknown status | 4 | 2008-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 704,374,637,739 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00885651 | Unknown status | 4 | 2008-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 704,374,637,739 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00885651 | Unknown status | 4 | 2008-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 704,374,637,739 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00885651 | Unknown status | 4 | 2008-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 704,374,637,739 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00885651 | Unknown status | 4 | 2008-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 704,374,637,739 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01132846 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 730,144,441,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01132846 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 730,144,441,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01132846 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 730,144,441,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01132846 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 730,144,441,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01132846 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 730,144,441,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01132846 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 730,144,441,857 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02012075 | Unknown status | 3 | 2013-12-01 | null | null | null | Phase III+ | Phase II+ | 1,013,612,282,436 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02012075 | Unknown status | 3 | 2013-12-01 | null | null | null | Phase III+ | Phase II+ | 1,013,612,282,436 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02012075 | Unknown status | 3 | 2013-12-01 | null | null | null | Phase III+ | Phase II+ | 1,013,612,282,436 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02012075 | Unknown status | 3 | 2013-12-01 | null | null | null | Phase III+ | Phase II+ | 1,013,612,282,436 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02012075 | Unknown status | 3 | 2013-12-01 | null | null | null | Phase III+ | Phase II+ | 1,013,612,282,436 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02012075 | Unknown status | 3 | 2013-12-01 | null | null | null | Phase III+ | Phase II+ | 1,013,612,282,436 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00517725 | Completed | 4 | 2007-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,151,051,235,951 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00517725 | Completed | 4 | 2007-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,151,051,235,951 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00517725 | Completed | 4 | 2007-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,151,051,235,951 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00517725 | Completed | 4 | 2007-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,151,051,235,951 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00517725 | Completed | 4 | 2007-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,151,051,235,951 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00517725 | Completed | 4 | 2007-07-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,151,051,235,951 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00348504 | Completed | 3 | 2003-03-01 | null | null | null | Phase III+ | Phase II+ | 1,322,849,927,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00348504 | Completed | 3 | 2003-03-01 | null | null | null | Phase III+ | Phase II+ | 1,322,849,927,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00348504 | Completed | 3 | 2003-03-01 | null | null | null | Phase III+ | Phase II+ | 1,322,849,927,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00348504 | Completed | 3 | 2003-03-01 | null | null | null | Phase III+ | Phase II+ | 1,322,849,927,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00348504 | Completed | 3 | 2003-03-01 | null | null | null | Phase III+ | Phase II+ | 1,322,849,927,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00348504 | Completed | 3 | 2003-03-01 | null | null | null | Phase III+ | Phase II+ | 1,322,849,927,333 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Invalid_Reason | Invalid_Reason | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT02767024 | Withdrawn | 4 | 2018-05-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 1,511,828,490,093 | No patients enrolled | Phase 4 | 01/05/2018 | Withdrawn | 31/10/2018 | 01/06/2018 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01930734 | Unknown status | 4 | 2013-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,571,958,030,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01930734 | Unknown status | 4 | 2013-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,571,958,030,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01930734 | Unknown status | 4 | 2013-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,571,958,030,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01930734 | Unknown status | 4 | 2013-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,571,958,030,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01930734 | Unknown status | 4 | 2013-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,571,958,030,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT01930734 | Unknown status | 4 | 2013-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,571,958,030,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00272805 | Completed | 3 | 2005-10-01 | null | null | null | Phase III+ | Phase II+ | 1,606,317,769,549 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00272805 | Completed | 3 | 2005-10-01 | null | null | null | Phase III+ | Phase II+ | 1,606,317,769,549 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00272805 | Completed | 3 | 2005-10-01 | null | null | null | Phase III+ | Phase II+ | 1,606,317,769,549 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00272805 | Completed | 3 | 2005-10-01 | null | null | null | Phase III+ | Phase II+ | 1,606,317,769,549 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00272805 | Completed | 3 | 2005-10-01 | null | null | null | Phase III+ | Phase II+ | 1,606,317,769,549 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0003144 | NCT00272805 | Completed | 3 | 2005-10-01 | null | null | null | Phase III+ | Phase II+ | 1,606,317,769,549 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000043591 | EFO_0007149 | NCT04717193 | Recruiting | 2 | 2021-05-28 | null | null | null | null | Phase II+ | 257,698,039,385 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0007149 | NCT04717193 | Recruiting | 2 | 2021-05-28 | null | null | null | null | Phase II+ | 257,698,039,385 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_0007149 | NCT04717193 | Recruiting | 2 | 2021-05-28 | null | null | null | null | Phase II+ | 257,698,039,385 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_1001923 | NCT02422017 | Completed | 2 | 2015-04-01 | null | null | null | null | Phase II+ | 712,964,572,005 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000651 | phenotype | Other | 4 | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_1001923 | NCT02422017 | Completed | 2 | 2015-04-01 | null | null | null | null | Phase II+ | 712,964,572,005 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000651 | phenotype | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000043591 | EFO_1001923 | NCT02422017 | Completed | 2 | 2015-04-01 | null | null | null | null | Phase II+ | 712,964,572,005 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000651 | phenotype | Other | null | LoF tolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000053747 | EFO_0009606 | NCT00996684 | Unknown status | 2 | 2009-10-01 | null | null | null | null | Phase II+ | 764,504,179,156 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0024458 | disease of visual system | Other | 2 | LoF tolerant | Detected in many | Low tissue specificity | none | chembl | known_drug | 413,311 |
ENSG00000053747 | EFO_0009606 | NCT00996684 | Unknown status | 2 | 2009-10-01 | null | null | null | null | Phase II+ | 764,504,179,156 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0024458 | disease of visual system | Other | null | LoF tolerant | Detected in many | Low tissue specificity | none | chembl | known_drug | 413,311 |
ENSG00000053747 | EFO_0009606 | NCT00996684 | Unknown status | 2 | 2009-10-01 | null | null | null | null | Phase II+ | 764,504,179,156 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0024458 | disease of visual system | Other | null | LoF tolerant | Detected in many | Low tissue specificity | none | chembl | known_drug | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 0 | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 0 | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 0 | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | impc | animal_model | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | impc | animal_model | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | europepmc | literature | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000055118 | EFO_0000318 | NCT02924285 | Completed | 3 | 2017-11-01 | null | null | null | Phase III+ | Phase II+ | 266,287,972,559 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF intolerant | Detected in many | Tissue enhanced | from1to10 | impc | animal_model | 413,311 |
ENSG00000061918 | EFO_0004278 | NCT03079102 | Terminated | 2 | 2017-08-21 | Terminated | stopped | null | null | Phase II+ | 77,309,411,797 | Slow enrollment and planned change of institution by PI | Phase 2 | 21/08/2017 | Terminated | 25/05/2021 | 02/06/2020 | Study_Staff_Moved | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 2 | LoF tolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000061918 | EFO_0004278 | NCT03079102 | Terminated | 2 | 2017-08-21 | Terminated | stopped | null | null | Phase II+ | 77,309,411,797 | Slow enrollment and planned change of institution by PI | Phase 2 | 21/08/2017 | Terminated | 25/05/2021 | 02/06/2020 | Study_Staff_Moved | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
Subsets and Splits